$-0.56 EPS Expected for ACADIA Pharmaceuticals Inc. (ACAD); CONSORTEUM HOLDINGS (CSRH) Shorts Up By 68400%

April 17, 2018 - By Henry Gaston

CONSORTEUM HOLDINGS INC (OTCMKTS:CSRH) had an increase of 68400% in short interest. CSRH’s SI was 137,000 shares in April as released by FINRA. Its up 68400% from 200 shares previously. It closed at $0.0008 lastly. It is down 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Analysts expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to report $-0.56 EPS on May, 8.They anticipate $0.16 EPS change or 22.22% from last quarter’s $-0.72 EPS. After having $-0.55 EPS previously, ACADIA Pharmaceuticals Inc.’s analysts see 1.82% EPS growth. The stock increased 4.90% or $0.93 during the last trading session, reaching $19.91. About 716,569 shares traded. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has declined 36.38% since April 17, 2017 and is downtrending. It has underperformed by 47.93% the S&P500.

Among 12 analysts covering ACADIA Pharmaceuticals (NASDAQ:ACAD), 9 have Buy rating, 0 Sell and 3 Hold. Therefore 75% are positive. ACADIA Pharmaceuticals had 35 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Thursday, July 27. Piper Jaffray maintained the shares of ACAD in report on Thursday, October 5 with “Buy” rating. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Neutral” rating by Roth Capital on Wednesday, October 19. On Wednesday, August 9 the stock rating was maintained by Cowen & Co with “Buy”. The stock has “Buy” rating by H.C. Wainwright on Thursday, October 5. The firm has “Buy” rating by Needham given on Friday, September 15. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Buy” rating by JP Morgan on Friday, September 4. The firm has “Buy” rating by Bank of America given on Tuesday, November 8. The stock of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) earned “Buy” rating by Needham on Tuesday, April 10. Jefferies maintained it with “Buy” rating and $47.0 target in Monday, September 4 report.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company has market cap of $2.48 billion. The Company’s lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis. It currently has negative earnings. The firm has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain.

Investors sentiment increased to 1.26 in Q4 2017. Its up 0.25, from 1.01 in 2017Q3. It improved, as 30 investors sold ACADIA Pharmaceuticals Inc. shares while 47 reduced holdings. 32 funds opened positions while 65 raised stakes. 117.35 million shares or 3.35% more from 113.55 million shares in 2017Q3 were reported. Polar Cap Llp holds 0.02% in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) or 50,000 shares. San Francisco Sentry Investment Grp Incorporated (Ca) holds 0.05% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 5,727 shares. Parallax Volatility Advisers Ltd Partnership invested in 0% or 607 shares. Alpine Woods Cap Invsts Ltd Liability Corporation has 0.03% invested in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 21,000 shares. Balyasny Asset Mgmt Ltd Liability Corp owns 357,958 shares. Qvt Fincl Limited Partnership accumulated 31,046 shares or 0.05% of the stock. Acuta Prtn Ltd Liability Corporation reported 90,000 shares. Pictet Asset, a United Kingdom-based fund reported 1.42 million shares. Natixis holds 0% of its portfolio in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) for 12,489 shares. Platinum Investment Management holds 32,300 shares or 0.03% of its portfolio. Hsbc Holdg Public Ltd Com accumulated 13,557 shares. Hollencrest Mngmt owns 7,985 shares for 0.03% of their portfolio. Dimensional Fund Advsrs Limited Partnership accumulated 11,543 shares. Profund Advsrs Llc invested in 0.04% or 35,978 shares. Utah Retirement Sys invested in 18,200 shares or 0.01% of the stock.

Since January 2, 2018, it had 1 insider purchase, and 3 selling transactions for $3.94 million activity. Another trade for 10,000 shares valued at $234,910 was bought by SOLAND DANIEL B. 74,321 shares valued at $2.24M were sold by Baity Glenn on Tuesday, January 2. $751,543 worth of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) was sold by Brege Laura on Tuesday, January 2.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts